TD Securities upgraded Tempus AI (TEM) to Buy from Hold with a price target of $65, down from $70. The shares are down over 50% in the last six months while the company’s fundamentals have strengthened, the analyst tells investors in a research note. TD believes Tempus AI’s Insights business is well positioned to accelerate growth in 2026 and benefit from pharma’s increased demand for AI research and development offerings. In addition, the company’s genomics growth momentum should continue, adds the firm. TD says Tempus AI’s AI risk is overdone in the share price, creating an attractive valuation.
Claim 55% Off TipRanks
Trade TEM with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI initiated with an Underperform at Jefferies
- William Blair health diagnostics analyst holds analyst/industry conference call
- Tempus AI announce strategic collaboration with Gilead
- Largest borrow rate increases among liquid names
- Tempus AI announces results from ALERT trial, study met primary endpoint